154 related articles for article (PubMed ID: 12675332)
1. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
[TBL] [Abstract][Full Text] [Related]
2. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
[TBL] [Abstract][Full Text] [Related]
3. Duration of an intermittent episode of viremia.
Di Mascio M; Percus JK; Percus OE; Markowitz M; Ho DD; Perelson AS
Bull Math Biol; 2005 Jul; 67(4):885-900. PubMed ID: 15893558
[TBL] [Abstract][Full Text] [Related]
4. The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed.
Percus JK; Percus OE; Di Mascio M
J Theor Biol; 2009 Apr; 257(3):454-9. PubMed ID: 19171155
[TBL] [Abstract][Full Text] [Related]
5. Viral load assay sensitivity and low level viremia in HAART treated HIV patients.
Verhofstede C; Van Wanzeele F; Reynaerts J; Mangelschots M; Plum J; Fransen K
J Clin Virol; 2010 Apr; 47(4):335-9. PubMed ID: 20138803
[TBL] [Abstract][Full Text] [Related]
6. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
7. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
J Infect Dis; 2007 Dec; 196(12):1773-8. PubMed ID: 18190257
[TBL] [Abstract][Full Text] [Related]
8. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
9. [Non conventional virological markers in HIV-infected patients: T-HIV DNA, 2LTR-HIV DNA and HIV RNA].
Gariglio R; Taborda MA; Bortolozzi R; McDermott JL; Martini I; Borgognone M; Villanova GV; Varnier OE; Giri AA
Medicina (B Aires); 2004; 64(5):419-28. PubMed ID: 15560543
[TBL] [Abstract][Full Text] [Related]
10. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.
Macias J; Palomares JC; Mira JA; Torres MJ; García-García JA; Rodríquez JM; Vergera S; Pineda JA
J Infect; 2005 Oct; 51(3):195-200. PubMed ID: 16230215
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
[TBL] [Abstract][Full Text] [Related]
12. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
[TBL] [Abstract][Full Text] [Related]
13. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
Di Mascio M; Markowitz M; Louie M; Hurley A; Hogan C; Simon V; Follmann D; Ho DD; Perelson AS
J Virol; 2004 Oct; 78(19):10566-73. PubMed ID: 15367623
[TBL] [Abstract][Full Text] [Related]
15. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management.
Garrett NJ; Apea V; Nori A; Ushiro-Lumb I; Oliver AR; Baily G; Clark DA
J Clin Virol; 2012 Apr; 53(4):354-5. PubMed ID: 22261125
[TBL] [Abstract][Full Text] [Related]
17. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
18. Quantification of human immunodeficiency virus-1 viral load using nucleic acid sequence-based amplification (NASBA) in north central Nigeria.
Forbi JC; Gabadi S; Iperepolu HO; Esona MD; Agwale SM
Niger J Clin Pract; 2010 Sep; 13(3):284-7. PubMed ID: 20857786
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
Jones LE; Perelson AS
Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.
Zhang J; Crumpacker CS
J Infect Dis; 2001 Nov; 184(10):1341-4. PubMed ID: 11679927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
